Sangamo Therapeutics Reports Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St set for higher open but weekly losses loom
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Sangamo Biosciences (SGMO) Reports Q2 Loss of $0.17/Share
August 9, 2017 4:08 PM EDTSangamo Biosciences (NASDAQ: SGMO) reported Q2 EPS of ($0.17), versus ($0.38) reported last year. Revenue for the quarter came in at $8.3 million, versus $3.7 million reported last year.
GUIDANCE:
Sangamo Biosciences sees FY2017 revenue of $30-40 million, versus the consensus of $31.2 million.
For... More
